Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Keratosis, Actinic 3Uterine Cervical Dysplasia 2Glioblastoma 2Pigmentation Disorders 1Neoplasms 1Melanoma 1Hemangioma, Capillary 1Glioma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms 1Brain Neoplasms 1Atypical Squamous Cells of the Cervix 1

Interventions

Temozolomide 4Surgical Procedures, Operative 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Gadolinium DTPA 2Filgrastim 2Erlotinib Hydrochloride 2Congresses as Topic 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2vitespin 1sargramostim 1picropodophyllin 1marizomib 1imetelstat 1gadobutrol 1gadobenic acid 1fluorodopa F 18 1bempegaldesleukin 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Transurethral Resection of Bladder 1Topotecan 1Thiotepa 1Ritonavir 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Perfusion Magnetic Resonance Imaging 1O(6)-benzylguanine 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Ependymoma × Imiquimod × Clear all
NCT01795313 2026-02-05

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

University of Pittsburgh

Phase 1 Terminated
23 enrolled

Ependymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡